Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.26 | 11.7647058824 | 2.21 | 2.6 | 2.21 | 507476 | 2.43236351 | CS |
4 | 0.16 | 6.92640692641 | 2.31 | 2.6 | 2.06 | 322714 | 2.30051747 | CS |
12 | 0.34 | 15.9624413146 | 2.13 | 2.81 | 2 | 391524 | 2.35706036 | CS |
26 | 0.6 | 32.0855614973 | 1.87 | 2.81 | 1.38 | 381172 | 2.05874537 | CS |
52 | 0.7 | 39.5480225989 | 1.77 | 3.62 | 1.3 | 508561 | 2.10738045 | CS |
156 | -29.43 | -92.2570532915 | 31.9 | 46.4 | 1.3 | 540955 | 13.57231387 | CS |
260 | -19.33 | -88.6697247706 | 21.8 | 53.762 | 1.3 | 633817 | 21.0881709 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.